NCI-MATCH Press Center
Interview Requests
To arrange an interview with a spokesperson, please send an email or call 215.789.3631.
News Articles and Press Releases
April 26, 2021
A new study arm opens in NCI-MATCH, expanding patients’ potential to qualify for this precision medicine cancer clinical trial when they may not have other options. Press Release
October 14, 2020
NCI-MATCH data shows value of platform trials for patients with rare genomically driven cancers. Interview with lead investigator Keith T. Flaherty, MD. Precision Oncology News/GenomeWeb
October 13, 2020
NCI-MATCH precision medicine cancer trial makes a major contribution to tumor gene testing for cancer treatment selection. Journal of Clinical Oncology publishes molecular analysis of 6000 NCI-MATCH patients. Press Release
August 13, 2020
In the latest NCI-MATCH news, April K.S. Salama, MD, and colleagues report on Arm H. The combination of dabrafenib and trametinib elicited favorable response rates. This promising activity warrants more investigations in BRAF V600>-mutated tumors outside of currently approved indications. OncLive
February 20, 2020
The results of Arm Z1D in the NCI-MATCH trial continue to attract media attention. Nilofer Azad, MD (Johns Hopkins) talks about the activity of nivolumab in MMR-deficient cancers in a feature article. MedPage Today/ASCO Reading Room
January 7, 2020
Komal Jhaveri, MD, FACP (Memorial Sloan Kettering) is the primary author on the publication of NCI-MATCH Arm Q results, published in the Annals of Oncology. The antibody-drug conjugate ado-trastuzumab emtansine (T-DM1) has promising activity in HER2 amplified salivary gland tumors. Press Release
December 19, 2019
The Journal of Clinical Oncology reports results for Arm Z1D of NCI-MATCH. “The confirmed overall response rate for nivolumab in tumors with DNA mismatch repair deficiencies was 36%–or 15 of 42 patients with cancers other than colon,” says Nilofer Azad, MD (Johns Hopkins). Press Release
June 3, 2019
Arm H finds the combination of dabrafenib and trametinib effective in a heavily pre-treated cohort of 17 distinct tumor types–several rare–with BRAF mutations.“Arm H met its primary endpoint with an overall objective response rate of 33 percent,” said lead researcher April K. S. Salama, MD (Duke University). Press Release
November 12, 2018
Interest continues in the NCI-MATCH (EAY131) trial. This ongoing study enrolls 85 percent of cancer patients referred by designated commercial and academic tumor gene testing laboratories (seven – eight new patients per week). Findings from substudy Y are being presented at an international meeting. Press Release
June 4, 2018
NCI-MATCH (Molecular Analysis for Therapy Choice), the largest precision medicine trial of its kind, has achieved a milestone with the release of results of several treatment arms of the trial. The new results offer findings of interest for future cancer research that could ultimately play a role in bringing targeted treatments to patients with certain gene abnormalities. Press Release
May 31, 2018
Keith Flaherty, MD, ECOG-ACRIN study chair, comments on targeted drugs in an article on basket trials. Xconomy National
May 30, 2018
NCI-MATCH (EAY131) achieves a milestone with the release of patient outcomes results from Arms I, Q, and W at the American Society of Clinical Oncology (ASCO) 2018 annual meeting. Press Release
June 7, 2017
As the NCI-MATCH precision medicine cancer trial reaches its 6,000-patient tumor sequencing goal two years early, the trial continues with a new strategy to complete enrollment by casting a wider net for patients. Press Release
September 26, 2016
ECOG-ACRIN opens the quality-of-life research study, COMmunication and Education in Tumor Profiling (EAQ152) or ‘COMET’ today. COMET is an ancillary study to the NCI-MATCH (EAY131) trial, already underway. Press Release
August 16, 2016
The ECOG-ACRIN Cancer Research Group has received federal approval to add a quality-of-life research study, COMmunication and Education in Tumor Profiling (EAQ152) or ‘COMET’ to the NCI-MATCH (EAY131) trial, already underway. Press Release
May 26, 2016
The phase II precision medicine cancer trial, Molecular Analysis for Therapy Choice (NCI-MATCH or EAY131) is set to resume gene testing of patients on May 31, 2016, at 12:00 Noon Eastern Time. Press Release
August 17, 2015
ECOG-ACRIN opens the phase II precision medicine cancer trial, National Cancer Institute-Molecular Analysis for Therapy Choice (NCI-MATCH or EAY131), the largest, most scientifically rigorous precision medicine trial in cancer to date, to cancer centers and community hospitals nationwide. Press Release
June 1, 2015
National Cancer Institute and ECOG-ACRIN announce the July 2015 opening of the NCI-MATCH / EAY131 trial, a multi-arm phase II precision medicine study that seeks to determine whether targeted therapies for people whose tumors have specific gene mutations will be effective regardless of cancer type. Press Release
